Chemotherapy treatments provided by alternate site infusion providers (e.g., pharmacy- and home-based settings) have increased, with 25% growth in outpatient chemotherapy treatment from 2014 to 2020, notes Trilliant Health.
Industry analysts anticipate that both the ambulatory and home infusion market in the U.S. will grow consistently over the next five years, particularly for chemotherapy treatment. While diversification in setting of care has the potential to increase access and improve patient satisfaction, many community oncologists have expressed concerns about the ability to retain oversight of a patient’s treatment and care journey. Further, patient advocates and industry groups have warned against the lack of robust data on the safety and quality of alternate site chemotherapy infusions—particularly home infusion. Read more.
